Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance

Curr Top Med Chem. 2021;21(8):677-683. doi: 10.2174/156802662108210319145317.

Authors

Gabriela Seabra¹, Roberta Ferreira Ventura Mendes¹, Luiz Felipe Vieira Dos Santos Amorim¹, Ingrid Vianez Peregrino¹, Marta Helena Branquinha², André Luis Souza Dos Santos², Ana Paula Ferreira Nunes¹

Affiliations

¹ Laboratorio de Resistencia Bacteriana (RESBAC), Departamento de Microbiologia, Centro de Ciencias da Saude (CCS), Universidade Federal do Espirito Santo (UFES), Vitoria, Brazil.
² Laboratorio de Estudos Avancados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Goes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.

PMID: 34028347
DOI: 10.2174/156802662108210319145317

No abstract available

Publication types

Review

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Azithromycin / pharmacology*
Azithromycin / therapeutic use*
Bacterial Infections / drug therapy*
COVID-19 Drug Treatment*
Drug Resistance, Bacterial / drug effects*
Humans
Microbial Sensitivity Tests
SARS-CoV-2 / drug effects*

Substances

Anti-Bacterial Agents
Antiviral Agents
Azithromycin